Hatteras Venture Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Hatteras Venture Partners/Activity

Hatteras Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio company CREATE Medicines received approval to initiate a first-in-human Phase 1/2 trial of CAR-T candidate CRT-402 for autoimmune diseases.

CREATE Medicines

CREATE Medicines Hatteras Venture Partners

hatterasvp.comJUL 30, 2026

JUL 30, 2026

Milestone

Portfolio company Wildflower Health acquired Every Mother to expand core and pelvic floor care across pregnancy, postpartum, and midlife.

Wildflower Health

Wildflower Health Hatteras Venture Partners

hatterasvp.comJUL 21, 2026

JUL 21, 2026

Investment

Portfolio company HistoSonics announced a new financing round with participation from Yosemite and other strategic investors.

HistoSonics

HistoSonics Hatteras Venture Partners

hatterasvp.comJUN 22, 2026

JUN 22, 2026

Milestone

Portfolio company Cardiosense received FDA De Novo classification for its novel cardiac technology for heart failure care.

Cardiosense

Cardiosense Hatteras Venture Partners

hatterasvp.comJUN 1, 2026

JUN 1, 2026

Investment

Portfolio company CREATE Medicines raised $122M to advance its CAR-T therapies through human trials.

CREATE Medicines

CREATE Medicines Hatteras Venture Partners

hatterasvp.comMAY 14, 2026

MAY 14, 2026

Exit

Bayer announced its acquisition of portfolio company Perfuse Therapeutics to complement its ophthalmology pipeline.

Perfuse Therapeutics

Perfuse TherapeuticsHatteras Venture Partners

hatterasvp.comMAY 6, 2026

MAY 6, 2026

News

Press coverage of Hatteras finding creative ways to hold meetings at a crowded SF healthcare conference.

Hatteras Venture Partners

hatterasvp.comJAN 15, 2026

JAN 15, 2026

News

Hatteras honored portfolio company HistoSonics with the Charles A. Sanders Award for Entrepreneurial Excellence.

HistoSonics

HistoSonics Hatteras Venture Partners

hatterasvp.comNOV 6, 2025

NOV 6, 2025

New Fund

Hatteras closed over $200M across two new healthcare-focused funds, Hatteras Venture Partners VII and Hatteras Opportunity Fund I, coinciding with its 25th year and 100th portfolio investment.

Hatteras Venture Partners VII and Hatteras Opportunity Fund I

Hatteras Venture Partners

hatterasvp.comAUG 13, 2025

AUG 13, 2025

Essay

Hatteras shared an overview of the life sciences investment ecosystem in North Carolina's Research Triangle.

Research Triangle life sciences ecosystem overview

Hatteras Venture Partners

hatterasvp.comMAY 22, 2024

MAY 22, 2024

Essay

Hatteras published a white paper analyzing the resurgence of biotech M&A activity.

Hatteras White Paper on Biotech M&A

Hatteras Venture Partners

hatterasvp.comMAY 11, 2022

MAY 11, 2022